Literature DB >> 25876444

Disease activity free status in MS.

Fred D Lublin1.   

Abstract

Year:  2011        PMID： 25876444     DOI： 10.1016/j.msard.2011.08.001

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN： 2211-0348            Impact factor:   4.339


× No keyword cloud information.
  16 in total

1.  Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms.

Authors:  Jagannadha Avasarala
Journal:  Innov Clin Neurosci       Date:  2017-04-01

2.  Randomized study combining interferon and glatiramer acetate in multiple sclerosis.

Authors:  Fred D Lublin; Stacey S Cofield; Gary R Cutter; Robin Conwit; Ponnada A Narayana; Flavia Nelson; Amber R Salter; Tarah Gustafson; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2013-03-11       Impact factor: 10.422

3.  Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Authors:  Jordana Hughes; Vilija Jokubaitis; Alessandra Lugaresi; Raymond Hupperts; Guillermo Izquierdo; Alexandre Prat; Marc Girard; Pierre Duquette; Francois Grand'Maison; Pierre Grammond; Patrizia Sola; Diana Ferraro; Cristina Ramo-Tello; Maria Trojano; Mark Slee; Vahid Shaygannejad; Cavit Boz; Jeanette Lechner-Scott; Vincent Van Pesch; Eugenio Pucci; Claudio Solaro; Freek Verheul; Murat Terzi; Franco Granella; Daniele Spitaleri; Raed Alroughani; Jae-Kwan Jun; Adam Fambiatos; Anneke Van der Walt; Helmut Butzkueven; Tomas Kalincik
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

4.  Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.

Authors:  Douglas L Arnold; Peter A Calabresi; Bernd C Kieseier; Sarah I Sheikh; Aaron Deykin; Ying Zhu; Shifang Liu; Xiaojun You; Bjoern Sperling; Serena Hung
Journal:  BMC Neurol       Date:  2014-12-31       Impact factor: 2.474

Review 5.  "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.

Authors:  Gavin Giovannoni; Davorka Tomic; Jeremy R Bright; Eva Havrdová
Journal:  Mult Scler       Date:  2017-04-06       Impact factor: 6.312

Review 6.  Outcome Measures in Clinical Trials for Multiple Sclerosis.

Authors:  Caspar E P van Munster; Bernard M J Uitdehaag
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

7.  Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.

Authors:  Douglas L Arnold; Peter A Calabresi; Bernd C Kieseier; Shifang Liu; Xiaojun You; Damian Fiore; Serena Hung
Journal:  BMC Neurol       Date:  2017-02-10       Impact factor: 2.474

8.  An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM).

Authors:  Stephan Schmidt; Jürgen Koehler; Christine Winterstein; Petra Schicklmaier; Boris Kallmann
Journal:  Ther Adv Neurol Disord       Date:  2018-01-23       Impact factor: 6.570

Review 9.  Autologous haematopoietic stem cell transplantation for neurological diseases.

Authors:  Joachim Burman; Andreas Tolf; Hans Hägglund; Håkan Askmark
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-09-02       Impact factor: 10.154

Review 10.  Cognitive and neuropsychiatric disorders among MS patients from Latin America.

Authors:  Sandra Vanotti; Fernando J Caceres
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.